var title_f5_19_5424="US megaureter transverse";
var content_f5_19_5424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse ultrasonographic view of a megaureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5424=[""].join("\n");
var outline_f5_19_5424=null;
var title_f5_19_5425="Fish tank granuloma";
var content_f5_19_5425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Fish tank granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5425=[""].join("\n");
var outline_f5_19_5425=null;
var title_f5_19_5426="Pentetate indium disodium In-111: Drug information";
var content_f5_19_5426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentetate indium disodium In-111: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/62/19427?source=see_link\">",
"    see \"Pentetate indium disodium In-111: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13185902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Indium DTPA In 111",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13185904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13185939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cisternography:",
"     </b>",
"     Intrathecal (based on 70 kg patient): 0.5 mCi (18.5 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13185938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cisternography:",
"     </b>",
"     Intrathecal: Some institutions suggest a minimum dose to achieve a high diagnostic quality is 0.1 mCi (3.7 MBq).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13185905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Radionuclide cisternography",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13185916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Aseptic meningitis, meningitis, pyrexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Skin reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Vomiting",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13185906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13185908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13185909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13185910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended (per manufacturer)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13185911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In one patient report, only 0.2% of the administered dose was excreted in breast milk, which would have resulted in an infant dose of less than 1 mrem (0.01 mSv) if breast-feeding had not been interrupted. This amount is so low that interruption of breast-feeding is not necessary (Johnson, 1995).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Johnson TK and Stabin M, \"111In-DTPA Cisternography to Investigate a Possible Cerebrospinal Fluid (CSF) Leak,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 1995, 36(9):1723-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/19/5426/abstract-text/7658238/pubmed\" id=\"7658238\" target=\"_blank\">",
"        7658238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16803 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5426=[""].join("\n");
var outline_f5_19_5426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185902\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185904\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185939\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185938\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185905\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255271\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185916\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185906\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185908\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185909\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185910\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185911\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/62/19427?source=related_link\">",
"      Pentetate indium disodium In-111: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_19_5427="Weight-resistance training in patients with osteoarthritis";
var content_f5_19_5427=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Weight-resistance training in patients with osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5427/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5427/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5427/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5427/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5427/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5427/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/19/5427/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many conflicting theories on the best approach to achieving health through exercise. Each personal trainer, coach, and physical therapist has their own opinions as to what constitutes the best exercise program and how the exercises should be performed.",
"   </p>",
"   <p>",
"    The truth is that there is no perfect exercise or perfect technique. The most important benefit a person can achieve is learning basic fundamentals in training techniques in order to minimize the risk for injury and to maximize the overall health status and functional strength. This is especially true for the patient with osteoarthritis.",
"   </p>",
"   <p>",
"    This topic will review the basic aspects of setting up a weight-resistance training program for patients with osteoarthritis. Information directed at the patient, as well as a description and evaluation of the different exercises, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=see_link\">",
"     \"Patient guidelines for weight-resistance training in osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7621?source=see_link\">",
"     \"Weight-resistance exercises in patients with osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In planning an exercise program, the first step is to take into account the individual&rsquo;s health history. A medical screening should be performed prior to an exercise program in an attempt to detect any preexisting conditions, to reduce the chance of exacerbating any preexisting problems, and to minimize the possibility of injury.",
"   </p>",
"   <p>",
"    Some health factors to consider are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A personal or family history of coronary heart disease",
"     </li>",
"     <li>",
"      Pulmonary disease",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Musculoskeletal injuries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3687?source=see_link\">",
"     \"Exercise assessment and measurement of exercise capacity in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STRUCTURE OF THE EXERCISE PROGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second step in initiating an exercise program for patients with osteoarthritis is goal development. Setting a goal is helpful in determining the structure of the exercise program. Some considerations are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amount of weight",
"     </li>",
"     <li>",
"      Allowable range of motion",
"     </li>",
"     <li>",
"      Alignment of the body and joint",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Open- versus closed-chain exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with osteoarthritis of the knee, closed-chain exercises, which produce compressive forces, are preferred over open-chain exercises, which produce shear forces that increase risk of injury to the internal structures of the knee.",
"   </p>",
"   <p>",
"    An open-chain exercise which targets the knee produces shear forces on the internal structures of the knee, especially the anterior cruciate ligament (ACL). A shear force is a force applied parallel to the planes of an object but opposite in direction to whatever force is present. Shear forces on the knee are created by performing single joint exercises that do not require pushing off of the bottom of the foot while it is planted firmly on the ground or on a platform. The leg curl, leg extension, and hip",
"    <span class=\"nowrap\">",
"     abductor/adductor",
"    </span>",
"    are examples of open-chain exercises.",
"   </p>",
"   <p>",
"    Open-chain movements exercise the knee through a full range of motion. For people with arthritis, however, exercising through a full range of motion is not necessary and can be associated with significant risks. Other risk groups are individuals recovering from an",
"    <span class=\"nowrap\">",
"     anterior/posterior",
"    </span>",
"    cruciate ligament tear repair and those with patellar tracking abnormalities.",
"   </p>",
"   <p>",
"    Closed-chain exercises, which target the knee, stabilize the knee by the use of movements that require pushing through the bottom of the feet while they are firmly planted on the ground or on a platform. The squat, hack squat, leg press, lunges, and Smith-Machine squat are examples of closed-chain exercises. These exercises distribute loads over multiple aspects of the lower extremities; therefore, they do not cause stress on one particular joint. Since the hamstrings and the quadriceps are recruited during closed-chain exercises, there is a greater amount of stability given to the knee joint during range of motion.",
"   </p>",
"   <p>",
"    Closed-chain exercises provide compression forces on bones, which can lead to greater bone density and which can reduce the chances of osteoporosis in both men and women. On the other hand, open-chain exercises expose joints to greater shear forces, which can lead to joint deterioration and eventual joint destruction.",
"   </p>",
"   <p>",
"    One study compared closed- and open-chain exercises in patients with anterior cruciate deficient knees [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5427/abstract/1\">",
"     1",
"    </a>",
"    ]. Stress to the anterior cruciate ligament, as indicated by anterior tibial displacement, was minimized by using squat exercises (closed-chain) when compared with knee extension exercises (open-chain). The clinical importance of these differences was evaluated in a prospective, randomized study of patients undergoing rehabilitation after anterior cruciate ligament reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5427/abstract/2\">",
"     2",
"    </a>",
"    ]. At one-year follow-up, patients randomized to closed-chain exercises had fewer arthrometer side-to-side differences, had less patellofemoral pain, and returned to normal daily activities and sports sooner than those in the open-chain group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Machines versus free weights",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of these types of weight-resistance training has advantages and disadvantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105984810\">",
"    <span class=\"h3\">",
"     Machines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages and disadvantages of machines include:",
"   </p>",
"   <p>",
"    Advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is good for beginners",
"     </li>",
"     <li>",
"      Ensures proper form",
"     </li>",
"     <li>",
"      Isolates specific muscle groups",
"     </li>",
"     <li>",
"      Is good for rehabilitation",
"     </li>",
"     <li>",
"      Most machines provide good lower back support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Machines are not designed for all specific body types and sizes.",
"     </li>",
"     <li>",
"      Machines act upon a single joint whereas free weights can be used for multi-jointed exercises, thereby improving functional strength.",
"     </li>",
"     <li>",
"      Most machines allow movement along only one plane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105984833\">",
"    <span class=\"h3\">",
"     Free weights",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages and disadvantages of free weights include:",
"   </p>",
"   <p>",
"    Advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Provide a greater range of motion than machines",
"     </li>",
"     <li>",
"      Improve coordination and balance by recruiting synergistic and stabilizer muscles",
"     </li>",
"     <li>",
"      Provide a greater diversity of exercises. Workouts can be customized.",
"     </li>",
"     <li>",
"      Require the involvement of a spotter (an individual supervising an exercise for the purposes of safety). A spotter should ensure that the person engaged in the exercise does not lose control of the weights and that the exercise is executed correctly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Require a greater amount of hand and wrist strength",
"     </li>",
"     <li>",
"      If exercises are done incorrectly from a standing position, they can place excessive strain on the lower back.",
"     </li>",
"     <li>",
"      Require strict form in order for them to be safe and effective",
"     </li>",
"     <li>",
"      A supervised workout program is always considered far more advantageous than an unsupervised program. Supervised programs provide a greater exchange of knowledge, motivation, and safety [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5427/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105984843\">",
"    <span class=\"h1\">",
"     BASIC WEIGHT-RESISTANCE EXERCISES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic weight-resistance exercises and their relative efficacy are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7621?source=see_link\">",
"     \"Weight-resistance exercises in patients with osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105984850\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation of the fundamentals in training technique helps to minimize the risk for injury and to maximize overall health status and functional strength. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical screening should be performed prior to an exercise program to detect any preexisting conditions, including coronary risk factors, lung disease, and musculoskeletal injuries, and to reduce the chance of exacerbating such problems and the possibility of injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Goal development prior to beginning exercise includes consideration of the amount of weight, of the allowable range of motion, and of body and joint alignment. For patients with osteoarthritis of the knee, closed-chain exercises are preferred over open-chain exercises. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Structure of the exercise program'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Open- versus closed-chain exercises'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of machines may be preferred for individuals with less exercise experience, are good for rehabilitation, and generally offer good lower back support; however, they are not designed for all body types and sizes. Free weights provide greater range of motion and diversity, and workouts can be customized, although greater hand and wrist strength and strict form are required. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Machines versus free weights'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5427/abstract/1\">",
"      Mazur LJ, Yetman RJ, Risser WL. Weight-training injuries. Common injuries and preventative methods. Sports Med 1993; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5427/abstract/2\">",
"      Bynum EB, Barrack RL, Alexander AH. Open versus closed chain kinetic exercises after anterior cruciate ligament reconstruction. A prospective randomized study. Am J Sports Med 1995; 23:401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5504 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5427=[""].join("\n");
var outline_f5_19_5427=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H105984850\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STRUCTURE OF THE EXERCISE PROGRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Open- versus closed-chain exercises",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Machines versus free weights",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105984810\">",
"      - Machines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H105984833\">",
"      - Free weights",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105984843\">",
"      BASIC WEIGHT-RESISTANCE EXERCISES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105984850\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3687?source=related_link\">",
"      Exercise assessment and measurement of exercise capacity in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=related_link\">",
"      Patient guidelines for weight-resistance training in osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7621?source=related_link\">",
"      Weight-resistance exercises in patients with osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_19_5428="MRI arrhythmogenic right ventricular cardiomyopathy";
var content_f5_19_5428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F79386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F79386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    MRI arrhythmogenic right ventricular cardiomyopathy (ARVC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image A is a T1 weighted axial fast spin echo image (fat is bright) demonstrating fat in the right ventricular free wall (arrow). Image B is a T1 fat saturated image of similar orientation demonstrating suppression of subcutaneous and epicardial fat as well fat in the right ventricular free wall (arrow).",
"    <div class=\"footnotes\">",
"     ARVC: arrhythmogenic right ventricular cardiomyopathy; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5428=[""].join("\n");
var outline_f5_19_5428=null;
var title_f5_19_5429="Trimethoprim and polymyxin B: Drug information";
var content_f5_19_5429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethoprim and polymyxin B: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/23/40307?source=see_link\">",
"    see \"Trimethoprim and polymyxin B: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/5/38996?source=see_link\">",
"    see \"Trimethoprim and polymyxin B: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Polytrim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Polytrimethoprim;",
"     </li>",
"     <li>",
"      Polytrim&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Conjunctivitis, blepharoconjunctivitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop in affected eye(s) every 3 hours (maximum: 6 doses per day) for 7-10 days; has also been used 4 times daily for 5-7 days (Williams, 2013;",
"     <i>",
"      The Wills Eye Manual",
"     </i>",
"     , 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11587704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/5/38996?source=see_link\">",
"      see \"Trimethoprim and polymyxin B: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 months: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic: Trimethoprim 1 mg and polymyxin B sulfate 10,000 units per 1 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Polytrim&reg;: Trimethoprim 1 mg and polymyxin B sulfate 10,000 units per 1 mL (10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F231532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contamination of the applicator tip.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of surface ocular bacterial conjunctivitis and blepharoconjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Burning, itching, edema, rash, redness increased, stinging, tearing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trimethoprim, polymyxin B, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5207601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Trimethoprim may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Trimethoprim may decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): May increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Trimethoprim may decrease the excretion of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Trimethoprim may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: Trimethoprim may decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Memantine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F231527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8771688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events have been observed with trimethoprim in animal studies; animal reproduction studies have not been conducted with polymyxin B. Trimethoprim/polymyxin B is classified as pregnancy category C. Due to trimethoprim&rsquo;s potential effect on folic acid metabolism, trimethoprim should only be used during pregnancy if the benefit justifies the potential risk. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8771692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trimethoprim is excreted into breast milk; excretion of polymyxin B is not known/use caution.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8771691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of trimethoprim are found in breast milk. It is not known if polymyxin B is found in breast milk. The manufacturer recommends that caution be exercised when administering trimethoprim/polymyxin B to nursing women. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F231536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Polymyxin B-Trimethoprim Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit/mL 0.1% (10 mL): $13.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Polytrim Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit/mL 0.1% (10 mL): $52.88",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F231537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Destrim (CO);",
"     </li>",
"     <li>",
"      Neoftalm (AR);",
"     </li>",
"     <li>",
"      Oftlamotrim (MY);",
"     </li>",
"     <li>",
"      Polytrim (AT, BE, NL, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Trimethoprim and polymyxin B are systemically absorbed following ophthalmic installation. Peak concentrations were trimethoprim 0.03 mcg/mL and polymyxin B 1 unit/mL.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       The Wills Eye Manual",
"      </i>",
"      , Chapter 5, \"Conjunctiva/Sclera/Iris/External Disease,\" 4th ed, Kunimoto DY, Kanitkar KD, and Makar MS, eds, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams L, Malhotra Y, Murante B, et al, &ldquo;A Single-Blinded Randomized Clinical Trial Comparing Polymyxin B-Trimethoprim and Moxifloxacin for Treatment of Acute Conjunctivitis in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2013, 162(4):857-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/19/5429/abstract-text/23092529/pubmed\" id=\"23092529\" target=\"_blank\">",
"        23092529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10102 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5429=[""].join("\n");
var outline_f5_19_5429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231539\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231549\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231541\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11587704\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231542\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231530\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231520\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231532\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231531\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231547\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231535\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5207601\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231546\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231526\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231527\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771688\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771692\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771691\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231536\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231537\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231534\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/23/40307?source=related_link\">",
"      Trimethoprim and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/5/38996?source=related_link\">",
"      Trimethoprim and polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_19_5430="Seminiferous epithelium";
var content_f5_19_5430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Seminiferous epithelium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the seminiferous epithelium. Tight junctions between Sertoli cells separate the tissue into two functional compartments: the basal compartment consists of the Leydig cells, the boundary tissue of the tubules including the peritubular myoid cells, and the outer layers of the tubules containing the spermatogonia; the adluminal compartment contains the inner portion of the tubules, including primary spermatocytes and more advanced stages of spermatogenesis. Developing germ cells are embedded in the Sertoli cell cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Griffin JE, Wilson JD. In: Williams Textbook of Endocrinology, 7th ed, Wilson JD, Foster DW (Eds), WB Saunders, Philadelphia, 1985, p. 802.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5430=[""].join("\n");
var outline_f5_19_5430=null;
var title_f5_19_5431="Acute cholangitis III - high power";
var content_f5_19_5431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute cholangitis (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are many neutrophiles in the tissue surrounding and in a bile duct cut in cross-section. The blue bands of connective tissue are separated by clear areas of edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5431=[""].join("\n");
var outline_f5_19_5431=null;
var title_f5_19_5432="Melasma cheek";
var content_f5_19_5432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64109%7EDERM%2F52220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64109%7EDERM%2F52220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A mottled hyperpigmented patch is present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperpigmented patch is present on the upper lip in this patient with melasma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5432=[""].join("\n");
var outline_f5_19_5432=null;
var title_f5_19_5433="Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas";
var content_f5_19_5433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5433/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5433/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5433/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5433/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5433/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/19/5433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evolution of an indolent non-Hodgkin lymphoma (NHL) to an aggressive histology is known as histologic transformation (HT). HT is a frequent occurrence for all subtypes of indolent B cell lymphoproliferative disorders, and occurs at a rate of approximately 3 percent per year. This complication presents with a rapid change in the clinical behavior of the disease, with evidence of a highly proliferative malignancy having a propensity to involve extranodal sites.",
"   </p>",
"   <p>",
"    The pathobiology and treatment of HT will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/1\">",
"     1",
"    </a>",
"    ]. The pathobiology and treatment of the indolent lymphomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=see_link\">",
"     \"Treatment of marginal zone (MALT) lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic transformation (HT) has been observed in a number of indolent B cell lymphoproliferative disorders, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Follicular lymphoma (FL)",
"     </li>",
"     <li>",
"      Marginal zone lymphomas (MZL, MALT lymphoma)",
"     </li>",
"     <li>",
"      Lymphoplasmacytic lymphoma (LPL, Waldenstr&ouml;m macroglobulinemia)",
"     </li>",
"     <li>",
"      Small lymphocytic lymphoma",
"      <span class=\"nowrap\">",
"       (SLL)/B",
"      </span>",
"      cell chronic lymphocytic leukemia (CLL). This form of HT has been termed Richter's transformation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"       \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     When to suspect HT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should suspect HT in a patient with previously-diagnosed indolent NHL who has developed rapid progression of lymphadenopathy, infiltration of uncommon extranodal sites (excluding the bone marrow), development of systemic symptoms (eg, fever, weight loss, night sweats), elevated serum lactate dehydrogenase,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercalcemia.",
"   </p>",
"   <p>",
"    The emergence of foci of intense uptake on PET scanning should also raise the suspicion of HT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/2\">",
"     2",
"    </a>",
"    ]. In LPL, additional clinical findings accompanying HT may include worsening cytopenias and organomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/3\">",
"     3",
"    </a>",
"    ]. However, these observations should always be confirmed histologically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'PET scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     De novo presentation of HT",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion a patient may present with diffuse large B-cell lymphoma (DLBCL) with discordant histologic features (ie, presence of a component of small B-cell proliferation in the bone marrow or elsewhere in a patient with large B-cell involvement elsewhere) suggesting HT of a previously undiagnosed indolent lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. In one study of 60 such patients, the following adverse clinical characteristics (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 1",
"    </a>",
"    ) were present at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disseminated disease &mdash; 97 percent",
"     </li>",
"     <li>",
"      Increased serum LDH levels &mdash; 55 percent",
"     </li>",
"     <li>",
"      More than one extranodal site involved &mdash; 50 percent",
"     </li>",
"     <li>",
"      Poor performance status &mdash; 33 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete remission with multiagent chemotherapy was achieved in 60 percent of the patients; 48 percent relapsed with an aggressive (28 percent) or indolent (20 percent) histology. Patients with HT at diagnosis had similar overall survival to a group of 180 patients with de novo DLBCL matched according to their age-adjusted IPI (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 1",
"    </a>",
"    ), but had a higher risk of indolent relapses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HT IN FOLLICULAR LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest body of information dealing with histologic transformation (HT) is related to its occurrence in follicular lymphoma (FL), which will be the focus of this review.",
"   </p>",
"   <p>",
"    HT is pathologically characterized in FL via loss of the follicular architecture as well as an accumulation of large cells, implying development of diffuse large B-cell lymphoma (DLBCL) (",
"    <a class=\"graphic graphic_picture graphicRef79473 \" href=\"UTD.htm?30/34/31268\">",
"     picture 1",
"    </a>",
"    ), less commonly Burkitt lymphoma (",
"    <a class=\"graphic graphic_picture graphicRef53282 \" href=\"UTD.htm?11/54/12135\">",
"     picture 2",
"    </a>",
"    ), or rarely a",
"    <span class=\"nowrap\">",
"     blastic/blastoid",
"    </span>",
"    transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Histologically, these tumors resemble de novo DLBCL or other aggressive or highly aggressive histologies, and have high Ki-67 staining and transferrin receptor-related protein, indicators of a high proliferative index [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/12\">",
"     12",
"    </a>",
"    ]. Using tissue microarrays of paired samples of FL pre- and post-HT, 89 percent of cases expressed a germinal center (GC) phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Immunophenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiologic mechanism behind the transformation of FL to a high grade histology is unknown. Potential mechanisms include divergent evolution of the two tumor populations from a common progenitor cell or the emergence of a more aggressive subclone from the FL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Frequency of transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of HT in FL varies from 10 to 70 percent, and is dependent on the definition of HT, length of follow up, and whether biopsies or autopsies were performed to document HT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. In general, however, these risks have been reported to range from 1.4 to 4.4 percent per year, as shown in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two series of patients with FL the probability of HT was 17 to 22 percent at five years and 28 to 31 percent at 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/16,19\">",
"       16,19",
"      </a>",
"      ]. In one of these series, no instances of HT were seen after 16 years, at which time the cumulative probability of HT was 39 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based analysis of 600 patients with follicular lymphoma diagnosed and treated in Canada followed for a median of 109 months reported that 28 percent developed transformation at an annual risk of 3 percent; this risk continued, without plateau, beyond 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second series reported approximately equal likelihood of HT in FL, SLL, and LPL, with incidences of 20, 15, and 10 percent, respectively, at a median follow up of seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In splenic MZL 13 percent of patients have been reported to undergo HT with 5-, 10- and 15-year risks of 14, 21, and 39 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors for transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the ultimate development of HT at the time of initial presentation of FL have included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage III or IV disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased serum level of lactate dehydrogenase [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Beta-2 microglobulin level &gt;3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Serum albumin &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Grade III histology [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High follicular lymphoma International Prognostic Index (FLIPI) (",
"      <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/24\">",
"       24",
"      </a>",
"      ] or IPI (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lack of complete remission following initial treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In two studies, whether the patient received immediate or delayed treatment did not affect the risk of development of HT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/17,25\">",
"     17,25",
"    </a>",
"    ], while in a third study those who received delayed treatment had a higher risk of HT (hazard ratio 1.9 (95% CI 1.2-2.9)) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquisition and accumulation of additional genetic abnormalities appear to be responsible for HT of indolent lymphoma to a diffuse aggressive histology. The overwhelming majority of cases of DLBCL evolving from FL, MZL, and LPL, are clonally related [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast, in histologic (Richter's) transformation of chronic lymphocytic leukemia, the CLL clone and the transformed clone are related in only 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large number of other non-random secondary cytogenetic abnormalities have been described in FL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Although many of these accompany disease progression in which follicular architecture is retained, as well as following HT, detailed analysis has demonstrated widespread secondary chromosomal abnormalities at initial diagnosis and during the course of FL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/30\">",
"     30",
"    </a>",
"    ]. No single cytogenetic abnormality appears to be associated with HT. Listings of chromosomal gains and losses associated with HT have been presented elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common translocation in FL is t(14;18)",
"    <span class=\"nowrap\">",
"     (bcl-2/IgH),",
"    </span>",
"    being present in 85 percent of patients. Following HT, the",
"    <span class=\"nowrap\">",
"     bcl-2/IgH",
"    </span>",
"    rearrangement persists in virtually all cases, with identical nucleotide sequences in the original FL and the DLBCL samples [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Cytogenetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gene alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific genetic lesions have been identified in HT and provide insight into its pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/32\">",
"     32",
"    </a>",
"    ]. These include alterations in genes regulating proliferation, control of the cell cycle, and programmed cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of the TP53 gene have been reported in 26 percent and 80 percent of cases of transformed FL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. TP53 is similarly inactivated in about 20 percent of transformed MALT lymphomas by deletion or mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/35\">",
"     35",
"    </a>",
"    ]. In a report of serial biopsies from patients with FL, TP53 mutations were observed in 28 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/36\">",
"     36",
"    </a>",
"    ]. Although TP53 mutations were not present at diagnosis, in subsequent biopsies where the histology remained FL, 14 percent of cases had mutations, providing evidence that TP53 mutations can precede HT, occurring from six months to four years prior to transformation.",
"   </p>",
"   <p>",
"    Given the central role of the B cell lymphoma 6 (BCL-6) gene in DLBCL, investigators have examined BCL-6 alterations in HT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one study, BCL-6 translocations or deletions were reported in 39 percent of patients with FL who went on to develop HT, versus 14 percent in those that did not transform [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/39\">",
"     39",
"    </a>",
"    ]. However, both loss and gain of BCL-6 translocations were observed, suggesting that BCL-6 translocation is not required for HT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Alterations in BCL-6'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene expression profile (GEP) is a powerful tool to identify genes and pathways that are aberrantly expressed during carcinogenesis or transformation. GEP has been used in FL to better understand the pathogenesis of histologic transformation and to develop prognostic models to identify patients with aggressive or more indolent disease at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, the GEP of FL samples identified a \"pluripotency\" signature that may predict histologic transformation (HT) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/43\">",
"     43",
"    </a>",
"    ]. Such \"pluripotency\" signatures were rich in the expression of genes that are typically expressed by embryonic stem cells and had reduced expression of genes typically expressed by stromal cells. This suggests that patients with a FL GEP closer to an embryonic stem cell may be more likely to transform into a more aggressive non-Hodgkin lymphoma subtype.",
"   </p>",
"   <p>",
"    Another study examined paired specimens from 12 patients with HT of FL using GEP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/44\">",
"     44",
"    </a>",
"    ]. Of the known genes only one oncogene, c-myc, previously associated with HT was identified. Fifteen c-myc-regulated genes were also significantly altered in expression. Further analysis found that cases segregated into groups with increased or decreased expression of c-myc-regulated genes and a group with no significant change in these genes. Since c-myc controls proliferation as well as programmed cell death, increased expression of c-myc-regulated genes may enhance proliferation, whereas decreased expression may impede programmed cell death contributing to HT via other mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of GEP for patients with newly diagnosed FL is currently unknown. Importantly, one model did not predict for the future development of HT, supporting the notion that HT may not be inherent at initial diagnosis of FL, but rather reflects the progressive accumulation of additional genetic changes leading to a histologically and clinically distinct entity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HT generally have a poor prognosis, with a median OS of approximately one year [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/19\">",
"     19",
"    </a>",
"    ]. In one study patients achieving CR had improved survival (40.5 versus 11 months), with the following good prognostic features [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior CR for treatment of indolent lymphoma",
"     </li>",
"     <li>",
"      Absence of prior treatment",
"     </li>",
"     <li>",
"      CR following treatment for HT",
"     </li>",
"     <li>",
"      Normal serum lactate dehydrogenase activity",
"     </li>",
"     <li>",
"      Absence of marrow involvement",
"     </li>",
"     <li>",
"      Absence of systemic \"B\" symptoms",
"     </li>",
"     <li>",
"      Limited stage disease",
"     </li>",
"     <li>",
"      Treatment with a CHOP-like regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, the time from diagnosis and number of prior relapses did not have an impact on survival after HT. Similar good prognostic factors were noted in a second study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a third study, attainment of CR was associated with the extent of disease at HT, while prior therapy was not [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/23\">",
"     23",
"    </a>",
"    ]. The median survival for patients achieving CR was 6.8 years, suggesting that a limited subset of patients with HT treated with CHOP-like regimens experience long survival in remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly employed treatment regimens for patients with HT include conventional therapy (eg, CHOP or its variants), radioimmunotherapy, and high-dose therapy followed by hematopoietic cell transplantation. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Conventional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HT have generally been treated similarly to patients with de novo DLBCL. As an example, patients treated with CHOP-like regimens had a median survival of 12 months, with a three-year survival of 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/16\">",
"     16",
"    </a>",
"    ]. Extrapolating from the results of treating de novo DLBCL with CHOP plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (R-CHOP), it would appear that, unless a clinical trial option is available, the R-CHOP regimen should probably be the chemotherapy of choice for patients with HT (",
"    <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective analysis evaluated the outcomes of 108 patients with HT who were treated with R-CHOP (23 patients) or CHOP-like chemotherapy without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/46\">",
"     46",
"    </a>",
"    ]. None of the patients had previously received rituximab. At a median follow-up of three (R-CHOP) and seven years for the two patient groups, patients who had received R-CHOP had a significantly higher rate of five-year post-HT overall survival (61 versus 33 percent).",
"   </p>",
"   <p>",
"    Following recurrence, patients treated with salvage chemotherapy regimens usually obtain only limited benefit.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPOCH plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      has been reported in 18 patients with HT (ie, transformed DLBCL), with a median EFS of 12.4 months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial in which treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      was compared with treatment with Yttrium-labeled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       ibritumomab",
"      </a>",
"      tiuxetan, three of four patients with HT who received rituximab alone responded; duration of response was not reported [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An international phase II trial of single-agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      in patients with relapsed or refractory aggressive non Hodgkin lymphoma included a subset analysis of 23 patients with histological transformation of follicular lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/49\">",
"       49",
"      </a>",
"      ]. The overall response rate was 57 percent (26 percent complete) with a median progression-free survival of 7.7 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for patients with very limited disease who have not been previously treated for FL, a high percent of patients with HT will relapse quickly following achievement of CR with conventional treatment, suggesting that additional treatment is required, such as hematopoietic cell transplantation (HCT). The largest experience is with the use of autologous HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on results of high-dose therapy and autologous HCT in patients with relapsed DLBCL with chemosensitive disease, this strategy has also been successfully applied to patients with HT. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link&amp;anchor=H179016843#H179016843\">",
"     \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'Following histologic transformation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both myeloablative and non-myeloablative allogeneic HCT have been performed in patients with HT. This subject is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radioimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiolabeled anti-CD20 monoclonal antibodies have significant activity in patients with relapsed and refractory B cell NHL. Both Yttrium-labeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    tiuxetan and Iodine-labeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    have been investigated in patients with HT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'Clinical Trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported on nine patients who received Yttrium-labeled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"       ibritumomab",
"      </a>",
"      tiuxetan with an OR of 56 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/48\">",
"       48",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       CALGB/SWOG",
"      </span>",
"      is currently enrolling patients on a trial of ibritumomab tiuxetan in patients with documented HT to confirm these results.",
"     </li>",
"     <li>",
"      Fifty-eight evaluable patients with refractory HT treated with Iodine-labeled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/50\">",
"       50",
"      </a>",
"      ]. The median time from diagnosis was 80 months, and 48 percent had no response to their most recent treatment. The overall response rate was 53 percent, with a median response duration of 11 months. Twenty-nine patients had a CR with a median duration of 20 months, and median survival was 22 months.",
"     </li>",
"     <li>",
"      Iodine-labeled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"       tositumomab",
"      </a>",
"      has been investigated in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      refractory patients including 10 patients with HT [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/51\">",
"       51",
"      </a>",
"      ]. When these patients were analyzed along with patients who had non-follicular grade",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      histology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      masses &gt;7 cm, the OR and CR rates were 42 percent and 16 percent, respectively, with a three-year progression-free survival of 11 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase I data combining Iodine-labeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    with high-dose chemotherapy and autologous HCT may be attractive given the responses seen in these patients using radioimmunotherapy alone (see above). With this approach in relapsed and refractory patients with aggressive histologies, the CR rate was 57 percent, with OS and event-free survivals of 55 percent and 39 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5433/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Richter's transformation of CLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to treatment of Richter's transformation in patients with chronic lymphocytic leukemia is poor. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should suspect histologic transformation (HT) in a patient with previously-diagnosed indolent non-Hodgkin lymphoma (NHL) who has developed rapid progression of lymphadenopathy, infiltration of uncommon extranodal sites (excluding the bone marrow), development of systemic symptoms, elevated serum lactate dehydrogenase,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercalcemia. Additional clinical findings accompanying HT may include worsening cytopenias and organomegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by biopsy of an involved lymph node, organ, or bone marrow showing the presence of a more aggressive NHL variant (",
"    <a class=\"graphic graphic_picture graphicRef79473 \" href=\"UTD.htm?30/34/31268\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53282 \" href=\"UTD.htm?11/54/12135\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HT of the indolent NHLs are most often treated with chemotherapeutic regimens similar to those used for the treatment of the aggressive NHL variant, diffuse large B-cell lymphoma (DLBCL). However, given the fact that such treatments are rarely curative in HT, enrollment of the patient in a well-designed clinical trial should always be considered as a first choice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Limited stage disease with limited prior therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with HT, limited stage disease (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 4",
"      </a>",
"      ), and limited prior therapy do reasonably well with chemotherapy alone. Based on the success of the combination chemotherapy program CHOP plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-CHOP) (",
"      <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"       table 3",
"      </a>",
"      ) in the treatment of DLBCL, we suggest initial treatment with R-CHOP or a CHOP-like regimen (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Conventional therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We further suggest that such patients not receive additional maintenance or consolidation treatment unless they have refractory disease or develop a subsequent relapse (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with resistant or relapsed disease, we suggest enrollment in a clinical trial. If this is not available, we suggest that the patient be treated with a salvage regimen similar to that used in",
"      <span class=\"nowrap\">",
"       relapsed/resistant",
"      </span>",
"      aggressive lymphoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'Achieving a second response'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In selected younger patients with chemosensitive disease following such salvage treatment, we suggest that this be followed by autologous hematopoietic cell transplantation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link&amp;anchor=H179016843#H179016843\">",
"       \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'Following histologic transformation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Advanced stage disease and/or extensive prior therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the use of R-CHOP regimen (",
"      <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"       table 3",
"      </a>",
"      ) as initial therapy for patients with advanced stage disease (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 4",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extensive prior therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Remissions in such patients are rarely durable. We therefore further suggest that eligible patients consider autologous hematopoietic cell transplantation (HCT) following achievement of complete remission (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Eligibility for autologous HCT varies across countries and institutions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link&amp;anchor=H179016843#H179016843\">",
"       \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'Following histologic transformation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19241?source=see_link\">",
"       \"Determining eligibility for autologous hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with relapsed or resistant disease are expected to do poorly. Available treatment options include enrollment in a clinical trial, use of salvage chemotherapy similar to that employed in",
"      <span class=\"nowrap\">",
"       relapsed/resistant",
"      </span>",
"      aggressive NHL, or radioimmunotherapy (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Radioimmunotherapy'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      Since there is limited information concerning which of these options yields the best results, enrollment in a well-designed clinical trial is suggested as a first choice (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Autologous HCT is then suggested for selected patients with chemosensitive disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link&amp;anchor=H179016843#H179016843\">",
"       \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'Following histologic transformation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/1\">",
"      Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program 2005; :314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/2\">",
"      Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/3\">",
"      Lin P, Mansoor A, Bueso-Ramos C, et al. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstr&ouml;m macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 2003; 120:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/4\">",
"      Fisher DE, Jacobson JO, Ault KA, Harris NL. Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications. Cancer 1989; 64:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/5\">",
"      Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990; 8:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/6\">",
"      Robertson LE, Redman JR, Butler JJ, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol 1991; 9:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/7\">",
"      Hodges GF, Lenhardt TM, Cotelingam JD. Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol 1994; 101:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/8\">",
"      Cabanillas F, Velasquez WS, Hagemeister FB, et al. Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 1992; 79:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/9\">",
"      Ghesqui&egrave;res H, Berger F, Felman P, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 2006; 24:5234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/10\">",
"      Natkunam Y, Warnke RA, Zehnder JL, et al. Blastic/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases. Am J Surg Pathol 2000; 24:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/11\">",
"      Mohamed AN, Palutke M, Eisenberg L, Al-Katib A. Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genet Cytogenet 2001; 126:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/12\">",
"      Natkunam Y, Soslow R, Matolcsy A, et al. Immunophenotypic and genotypic characterization of progression in follicular lymphomas. Appl Immunohistochem Mol Morphol 2004; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/13\">",
"      Lee AM, Davies AJ, Clear A, Calaminici M. Tissue microarray is a useful tool in the evaluation of genes implicated in transformation of follicular lymphoma (abstract). Blood 2004; 104:624a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/14\">",
"      Carlotti E, Wrench D, Matthews J, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 2009; 113:3553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/15\">",
"      Eide MB, Liest&oslash;l K, Lingjaerde OC, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 2010; 116:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/16\">",
"      Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/17\">",
"      Al-tourah A, Chhanabhai M, Gill K, Hoskins P. Incidence, predictive factors and outcome of transformed lymphoma: a population-based study from British Columbia. Ann Oncol 2005; 16:v64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/18\">",
"      Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/19\">",
"      Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/20\">",
"      Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 2012; 157:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/21\">",
"      Bains P, Al Tourah A, Campbell BA, et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol 2013; 24:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/22\">",
"      Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:5165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/23\">",
"      Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001; 25:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/24\">",
"      Gine E, Lopez-Guillermo A, Montato S, Bosch F. FLIPI and histological subtype of the most important predicting factors of histological transformation in follicular lymphoma. Ann Oncol 2005; 16:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/25\">",
"      Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/26\">",
"      Zelenetz AD, Chen TT, Levy R. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. J Exp Med 1991; 173:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/27\">",
"      Foon KA, Thiruvengadam R, Saven A, et al. Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model. Ann Intern Med 1993; 119:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/28\">",
"      Viardot Aa, Barth TF, M&ouml;ller P, et al. Cytogenetic evolution of follicular lymphoma. Semin Cancer Biol 2003; 13:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/29\">",
"      Boonstra R, Bosga-Bouwer A, Mastik M, et al. Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma. Hum Pathol 2003; 34:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/30\">",
"      Lestou VS, Gascoyne RD, Sehn L, et al. Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 2003; 122:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/31\">",
"      Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88:3937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/32\">",
"      Lossos IS, Levy R. Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 2003; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/33\">",
"      Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/34\">",
"      Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/35\">",
"      Du M, Peng H, Singh N, et al. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995; 86:4587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/36\">",
"      Davies AJ, Lee AM, Taylor C, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 2005; 19:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/37\">",
"      Lossos IS, Levy R. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. Blood 2000; 96:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/38\">",
"      Lossos IS, Warnke R, Levy R. BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene. Leukemia 2002; 16:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/39\">",
"      Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003; 102:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/40\">",
"      Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/41\">",
"      Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/42\">",
"      Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/43\">",
"      Gentles AJ, Alizadeh AA, Lee SI, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood 2009; 114:3158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/44\">",
"      Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A 2002; 99:8886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/45\">",
"      Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007; 136:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/46\">",
"      Savage KJ, Gill KK, Klasa RJ, et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma (abstract 790). Blood 2007; 110:243a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/47\">",
"      Jermann M, Jost LM, Taverna Ch, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/48\">",
"      Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/49\">",
"      Czuczman MS, Vose JM, Witzig TE, et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 2011; 154:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/50\">",
"      Zelenetz A, Saleh M, Vose J, Younes A, Kaminski M. Patients with transformed low grade lymphoma attain durable responses following out-patient radioimmunotherapy with tositumomab and iodine I 131 tositumomab (abstract). Blood 2002; 100:357a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/51\">",
"      Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5433/abstract/52\">",
"      Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4724 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-ECAAE0F0B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5433=[""].join("\n");
var outline_f5_19_5433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      When to suspect HT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      De novo presentation of HT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HT IN FOLLICULAR LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Frequency of transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors for transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytogenetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gene alterations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Conventional therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radioimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Richter's transformation of CLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      General recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Limited stage disease with limited prior therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Advanced stage disease and/or extensive prior therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4724\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4724|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/34/31268\" title=\"picture 1\">",
"      Transformation FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12135\" title=\"picture 2\">",
"      Richters transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4724|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 1\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/23/37243\" title=\"table 2\">",
"      Follic lymphoma int prog index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/54/876\" title=\"table 3\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 4\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19241?source=related_link\">",
"      Determining eligibility for autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=related_link\">",
"      Hematopoietic cell transplantation in follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=related_link\">",
"      Treatment of marginal zone (MALT) lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_19_5434="Implantable cardioverter-defibrillators: Complications";
var content_f5_19_5434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Implantable cardioverter-defibrillators: Complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5434/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5434/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5434/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/19/5434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/19/5434/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/19/5434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implantable cardioverter-defibrillator (ICD) is highly effective in terminating ventricular tachyarrhythmias, including ventricular tachycardia (VT) and ventricular fibrillation (VF), thereby aborting sudden cardiac death (SCD). ICD use has been associated with improved survival due to fewer arrhythmic deaths, when compared to antiarrhythmic drugs in survivors of sudden cardiac death (SCD). There is also evidence of benefit when used for primary prevention in selected groups of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H13#H13\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention of SCD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a variety of potential complications associated with ICD use [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the rate of complications related to the ICD has fallen markedly with the evolution from a large device that required an abdominal pocket and insertion of an epicardial lead system via thoracotomy to the current use of much smaller transvenous pectoral devices [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In one report, the incidence of complications with nonthoracotomy ICDs was significantly lower with a pectoral compared to an abdominal generator site (6 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications associated with an ICD will be reviewed here. The general principles of the ICD, and recommendations for ICD use, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H26#H26\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H19#H19\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of ICD malfunction is difficult to determine due to inconsistent definitions and the lack of mandatory reporting. Information comes from small observational studies, as well as from annual reports filed with the United States Food and Drug Administration by companies that make devices and from voluntary registries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The latter sources generally include device malfunctions severe enough to require explantation.",
"   </p>",
"   <p>",
"    The incidence of a broad list of major and minor complications was illustrated in a prospective study of 778 patients receiving a transvenous ICD. The rate of freedom from any adverse event at 1, 3, and 12 months was 79, 68, and 51 percent, respectively&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/4\">",
"     4",
"    </a>",
"    ]. Among the complications that occurred, 60 percent were due to the ICD system, 29 percent were related to the implantation procedure, and 11 percent were not device related. The most common events were inappropriate detection and subsequent delivery of a shock (16 percent), which usually resolved with device reprogramming or drug readjustment,",
"    <span class=\"nowrap\">",
"     wound/pocket",
"    </span>",
"    problems (4 percent) and",
"    <span class=\"nowrap\">",
"     lead/ICD",
"    </span>",
"    can dislodgement or migration (3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Explantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malfunctions requiring explantation and early replacement are usually the most severe, and are also the easiest to track. A review of annual reports submitted to the FDA between 1990 and 2002 noted the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      8489 of 415,780 ICDs were explanted due to confirmed device malfunction (2.0 percent).",
"     </li>",
"     <li>",
"      From 1993 to 1996 the annual rate of explantation declined from 3.9 to 0.8 percent, but then increased again to a second peak of 3.6 percent in 2001.",
"     </li>",
"     <li>",
"      31 deaths were attributable to device malfunction between 1990 and 2002.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were reported in a meta-analysis of two registries, one from North America and one from Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/6\">",
"     6",
"    </a>",
"    ]. The meta-analysis included data from 1988 to 2004, with 6634 ICDs. A bimodal pattern similar to that observed in the FDA reports was described. The annual rate of ICD failure requiring explantation fell from 5.3 percent in 1989 to 0.6 percent in 1998, and then increased to a second peak of 2.6 percent in 2001. After 2001, the rate began falling again.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCEDURAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantation of an ICD system involves placement of the ICD lead system and the pulse generator. Current ICD lead systems are typically placed transvenously via the axillary, subclavian, or cephalic vein. Various lead systems approved for use involve one to three leads. This approach has largely replaced surgical epicardial lead placement, which was associated with appreciable mortality and with complications that are unique to thoracotomy and epicardial lead systems, such as the postpericardiotomy syndrome (postcardiac injury syndrome), pleural effusion, erosion of epicardial patches, constrictive pericarditis, and atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H12#H12\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Implantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link\">",
"     \"Post-cardiac injury syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported complication rates range from 3 to 6 percent, with up to one-half of these complications considered serious [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/8\">",
"     8",
"    </a>",
"    ]. Perioperative mortality with transvenous ICD implantation has ranged from 0.2 to 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/4,8-11\">",
"     4,8-11",
"    </a>",
"    ]. Higher in-hospital mortality rates were observed in a cohort of 26,887 heart failure patients undergoing ICD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CRT implantation that included older adults; rates ranged from 0.7 to 1.2 to 2.2 percent in patients aged &lt;80, 80 to 85, and &gt;85 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/12\">",
"     12",
"    </a>",
"    ]. When compared with those receiving a single-chamber ICD, patients receiving a dual-chamber ICD have a greater risk of complications (3.2 versus 2.1 percent, adjusted odds ratio [OR] 1.40, 95% CI 1.28-1.52) and in-hospital mortality (0.4 versus 0.23 percent, adjusted OR 1.45, 95% CI 1.20-1.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bleeding severe enough to require reoperation or transfusion has been reported in 2.2 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/10\">",
"     10",
"    </a>",
"    ]. Most lead dislodgements and infections occurred in the first three months, while lead fractures continued to occur during follow-up. Less common complications of lead placement included pneumothorax and cardiac perforation, seen in less than 1 percent of implantations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ICD generator is implanted subcutaneously or submuscularly in the pectoral region. A review of 1000 consecutive pectoral implantations found that subcutaneous implantation required less procedural time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/13\">",
"     13",
"    </a>",
"    ]. The overall complication rate was identical with the two approaches but, at six months, submuscular implantation was significantly less likely to lead to ICD erosion (0 versus 0.9 percent) and significantly more likely to lead to lead dislodgement or fracture (3.0 versus 0.8 percent). However, this study was performed with the initial generation of pectoral pulse generators. Current devices are substantially smaller and in most patients are implanted subcutaneously, usually without complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Operator characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;As indications for ICD implantation expand, devices are being implanted by larger numbers of clinicians with a wide range of procedural volumes and with different board certifications.",
"   </p>",
"   <p>",
"    The relationship between implant complications and operator volume was evaluated in a cohort of 9854 Medicare patients with ICDs implanted by 1672 clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/14\">",
"     14",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Average annual implant volume ranged from 1 to 87 devices, with a median annual volume of 7 implants per year.",
"     </li>",
"     <li>",
"      There was no correlation between operator volume and periprocedural mortality.",
"     </li>",
"     <li>",
"      90-day rates of mechanical complications (7 versus 4.4 percent) and ICD infection (1.3 versus 0.6 percent) were significantly higher among clinicians in the lowest quartile of implant volume compared to those in the highest. However, once a threshold of 11 implants per year was reached, the overall complication rate was no longer dependent upon volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association of clinician certification with the rates of ICD procedural complications was examined in a retrospective cohort study using data from a national ICD registry [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinicians were classified according to one of four categories of board certification, determined by review of databases of the American Board of Internal Medicine, Society for Thoracic Surgery, and the American College of Surgery: electrophysiologists, nonelectrophysiologist cardiologists, thoracic surgeons, and other specialists who were not certified by any of the above organizations at the time of data entry.",
"   </p>",
"   <p>",
"    The study evaluated patient data entered into the ICD registry between January 2006 and June 2007. The analysis included 111,293 patients who underwent initial transvenous ICD placement by 2128 clinicians in 1062 hospitals. Patients were excluded if their clinician submitted fewer than ten ICD procedures, if they were 18 years old or younger, if they had a prior ICD implantation, or if they had an epicardial lead placed.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians who were board certified in electrophysiology placed 71 percent of ICDs and had the lowest rates of overall and major complications (3.5 and 1.3 percent, respectively). Thoracic surgeons placed 1.7 percent of ICDs and had the highest rates of overall and major complications (5.8 and 2.5 percent). This difference was statistically significant (adjusted relative risk 1.44).",
"     </li>",
"     <li>",
"      Patients meeting criteria for implantation of an ICD capable of biventricular pacing were more likely to receive such a device if the treating clinician was an electrophysiologist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the generator pocket or leads has been reported in up to 7 percent of patients, with a higher incidence in pulse generator replacements than in initial implantation. The incidence appears to be lower with perioperative antibiotics, with the transvenous rather than the epicardial approach, and with pectoral implantation. Infection of an ICD can be devastating, and complete removal of the ICD generator and all leads and antibiotic therapy are strongly recommended. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30921?source=see_link\">",
"     \"Cardiac implantable electronic device lead removal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Explantation and generator change",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks associated with device explantation and generator change are different from those of initial implantation. Because new lead replacement is usually not required, lead related complications are uncommon. However, infections may still occur, and some evidence suggests that infections are more common following generator change than initial implant.",
"   </p>",
"   <p>",
"    The rate of complications associated with device explantation and generator change are an important issue for clinicians and patients considering early generator change due to a device advisory or recall. The reported rates of device failure in these recalls are usually very low, often well under one percent. Thus, even low procedure-related complication rates could outweigh the benefit of changing the device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30921?source=see_link&amp;anchor=H2425159623#H2425159623\">",
"     \"Cardiac implantable electronic device lead removal\", section on 'Advisory/recall'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue was highlighted in a study of 17 Canadian ICD centers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/16\">",
"     16",
"    </a>",
"    ]. Among 2915 patients with an ICD subject to an advisory, 533 patients had a device replaced. During a mean follow-up of 2.7 months, 8.1 percent of the patients who underwent replacement had a complication, including major complications requiring reoperation in 5.3 percent. Indications for reoperation included infection requiring extraction, hematoma, and system malfunction. Among patients requiring reoperation, there were two deaths: one due to right ventricular perforation after extraction of an infected lead, and one due to sepsis.",
"   </p>",
"   <p>",
"    During the study period, three of the devices subject to advisories experienced a malfunction (0.1 percent). None of these malfunctions resulted in adverse clinical sequelae, and all three patients subsequently underwent generator replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LEAD COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead-related problems include infection, as noted above, lead dislodgement, fracture, and insulation defects. Insulation defects are more common with systems using long transvenous leads tunneled to the abdomen and relatively larger generators [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/17\">",
"     17",
"    </a>",
"    ]. Subclavian vein thrombosis is a less common complication that can cause upper extremity swelling and discomfort and may interfere with placement of additional leads [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, fibrosis at the lead-myocardial interface can contribute to an increase in the defibrillation threshold. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Increased defibrillation threshold'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With transvenous lead systems, complications are related to the approach and site of generator placement. In a report from the AVID trial, the likelihood of complications was significantly higher with subclavian compared to cephalic vein access (14 versus 4 percent) and with an abdominal versus pectoral generator site (13 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/2\">",
"     2",
"    </a>",
"    ]. The most common complications were lead fracture, infection (2.8 percent each), lead dislodgement, and bleeding (1.5 percent each). Most dislodgements and infections occurred in the first three months, while lead fractures continued to occur during follow-up. Less common complications of lead placement included pneumothorax and cardiac perforation.",
"   </p>",
"   <p>",
"    An entirely subcutaneous ICD system has been evaluated but remains investigational; such a device would eliminate the need for transvenous leads and their associated potential complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H21112589#H21112589\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Subcutaneous ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lead failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of lead failure and the types of problems that occur have been evaluated in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/2,19-25\">",
"     2,19-25",
"    </a>",
"    ]. Reported lead failure rates have varied from 1 to 9 percent at two years, 2 to 15 percent at five years and 5 to 40 percent at eight to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/19,20,25\">",
"     19,20,25",
"    </a>",
"    ]. Comparison of rates are confounded by varying definitions of lead failure, differences among lead models, varying patient and clinician characteristics, and limitations of methods for detection of lead malfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/20\">",
"     20",
"    </a>",
"    ]. Certain lead models and sizes have been identified as prone to failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. However, it is difficult to separate the relative contribution of lead diameter and lead design with respect to failure rates.",
"   </p>",
"   <p>",
"    In a series of 1317 patients, the main reasons for lead malfunction were insulation defects (26 percent), artifact oversensing (24 percent), and lead fractures (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/19\">",
"     19",
"    </a>",
"    ]. Lead malfunction resulted in inappropriate ICD therapy in 76 percent of cases. If the integrity of the high-voltage part of the lead could be ascertained, only an additional",
"    <span class=\"nowrap\">",
"     pace/sense",
"    </span>",
"    lead was implanted. Otherwise, a new defibrillator lead was used. Regardless of lead revision strategy, the rate of recurrent ICD lead-related problems was 20 percent at five years. Deaths related to ICD lead failure have been reported but are exceedingly rare [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diameter of the ICD lead may also be associated with the likelihood of failure. In comparison with a retrospective cohort of patients who received ICD leads with diameters ranging from 8 French (2.67 mm) to 11 French (3.67 mm), ICD lead failure occurred significantly more often in patients who received 7 French (2.33 mm) ICD leads (2.3 versus 0.8 percent failure rate; adjusted HR 4.2 [95% CI 1.0-18.0]) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/25\">",
"     25",
"    </a>",
"    ]. The exact reason for differences in failure rates remains elusive as the design and construction of the leads are the same regardless of size.",
"   </p>",
"   <p>",
"    Although impedance monitoring is typically performed in patients with ICDs, it may be insufficient to warn of lead failure and prevent inappropriate shocks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/24\">",
"     24",
"    </a>",
"    ]. Oversensing may be detected more frequently and earlier than impedance changes in failing leads [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An algorithm combining oversensing and impedance measurements to detect coaxial ICD lead failure found a sensitivity of 83 percent (24 of 29) and a specificity of 100 percent in 667 patients when tested in a population with various lead models [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/28\">",
"     28",
"    </a>",
"    ]. The algorithm was subsequently modified to add features beyond lead failure detection, including a more extensive alerting system and the implementation of real-time, automatic changes to the VF detection parameters of the ICD when a lead failure is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/29\">",
"     29",
"    </a>",
"    ]. The algorithm was developed primarily for patients with Medtronic Sprint Fidelis leads, and it can be downloaded to Medtronic ICDs only. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30921?source=see_link&amp;anchor=H2425159623#H2425159623\">",
"     \"Cardiac implantable electronic device lead removal\", section on 'Advisory/recall'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lead removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is occasionally necessary to remove defibrillator or pacemaker leads, most often for infection or mechanical lead failure. Indications and outcomes for lead removal are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30921?source=see_link\">",
"     \"Cardiac implantable electronic device lead removal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tricuspid regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe tricuspid regurgitation (TR) can result from ICD or permanent pacemaker leads. In a report of 41 such patients (six with an ICD), the mean time from device placement to surgery was 72 months (range 2 to 228 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/30\">",
"     30",
"    </a>",
"    ]. One-half of patients presented with severe right heart failure, while the other half were found to have severe TR during evaluation for other cardiac abnormalities, such as mitral or aortic valve disease. The major mechanisms of tricuspid valve injury were lead impingement, adherence, perforation, and entanglement. Valve malfunction due to the lead could be diagnosed by transthoracic echocardiography in only five patients (12 percent). Tricuspid valve replacement was performed in 22 patients and annuloplasty in 19, leading to improvement in symptoms.",
"   </p>",
"   <p>",
"    Tricuspid regurgitation has also been reported amongst recipients of bioprosthetic tricuspid valves who subsequently undergo implantation of a permanent pacemaker (PPM) or ICD with a transvenous ventricular lead. In a retrospective cohort study of 323 patients who received a bioprosthetic tricuspid valve (58 patients with a",
"    <span class=\"nowrap\">",
"     PPM/ICD",
"    </span>",
"    lead, 265 patients without a lead) and were followed for a mean of over two years, there was a non-significant increase in the rate of moderate or severe TR in patients with a device lead (9 versus 5 percent), rates which compare favorably with the rate of TR development following transvenous lead placement through native tricuspid valves [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/31\">",
"     31",
"    </a>",
"    ]. While the study is limited due to its retrospective, non-randomized nature, these results suggest that transvenous device leads are relatively safe and feasible in patient with a bioprosthetic tricuspid valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PULSE GENERATOR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications related to the pulse generator include migration, skin erosion, and necrosis (due to the size and weight of the generator) and premature battery depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/2\">",
"     2",
"    </a>",
"    ]. Fortunately, these problems are uncommon, occurring in less than 2 percent of patients. In addition, hematomas or seromas can form in the pulse generator pocket.",
"   </p>",
"   <p>",
"    Although clinically important generator failure is uncommon, there have been a growing number of Food and Drug Administration (FDA) recalls and advisories because of potentially harmful consequences resulting from device malfunction. A review of FDA reports over a 10 year period found 52 advisories involving 114,645 ICDs and over 500,000 pacemakers; these were primarily related to hardware malfunction or computer errors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Shoulder-related problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder-related problems with the pectoral approach include decreased shoulder motility, pain, reduced function, and insertion tendinitis. These complaints do not require additional intervention or surgical revision and often abate by 12 months after insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subcutaneous rather than subpectoral generator location seems to be associated with a lower incidence of shoulder-related problems. Furthermore, the smaller size of newer pulse generators has made device-related shoulder problems extremely rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Twiddler's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twiddler's syndrome, in which twisting or rotating the device in its pocket results in lead dislodgement and device malfunction, can occur in patients with an ICD. It is most likely to develop when the device is implanted in the abdomen of an obese patient who is able to rotate it within the abdominal pocket but has been reported in other situations as well [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients most often present with an increase in bradycardic pacing threshold or lead impedance. However, there is a possibility that the device will fail to sense and treat an arrhythmia. Careful suturing of the device to the fascia, and matching pocket and device size are important to avoid this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Electronic circuit damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Device failures are uncommon, with reports estimating an incidence between 0.01 and 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/36\">",
"     36",
"    </a>",
"    ]. Electronic circuit failure can result from electrical overstress damage to the high voltage hybrid circuit and other electronic components [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/37\">",
"     37",
"    </a>",
"    ]. Signs of such failure include loss of telemetry and inability to deliver therapy. Electrical overstress damage may occur during capacitor reformation or charging and the delivery of a shock, after cardioversion, or with the use of electrocautery. It is recommended that routine follow-up examination of device function be performed in these settings. Radiation therapy can damage circuitry as well. Current recommendations include shielding the device from the radiation beam and careful follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of arrhythmia-related problems can occur in patients with an ICD. Arrhythmic complications include both inappropriate shocks, usually due to the treatment of supraventricular tachycardias, and appropriate shocks.",
"   </p>",
"   <p>",
"    A systematic review of seven trials of primary and secondary prevention of sudden cardiac death (SCD) noted that appropriate ICD therapies outnumbered SCD events in the control groups by a factor of two to three [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/38\">",
"     38",
"    </a>",
"    ]. Possible explanations for this finding include the treatment of arrhythmias that would have been hemodynamically tolerated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    terminated spontaneously (ie, nonfatal events), inaccurate characterization of events in the clinical trials, or a possible proarrhythmic effect of the devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Inappropriate shocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inappropriate shocks occur in 20 to 25 percent of patients with an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The main cause is supraventricular tachyarrhythmia (SVT), including sinus tachycardia, atrial fibrillation, and other rapid supraventricular arrhythmias as well as nonsustained VT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/41\">",
"     41",
"    </a>",
"    ]. Other causes include electrical noise, inappropriate sensing, and ICD malfunction (eg, lead fracture). Such patients may become quite uncomfortable since multiple inappropriate shocks are often delivered with SVT. However, whereas appropriate shocks may be associated with a worse prognosis (as a marker of worsening cardiac status compared to patients with ICDs who have not received an appropriate shock), there are conflicting data on an association between inappropriate shocks and mortality. While one retrospective study of ICD recipients showed no association between inappropriate shocks and reduced survival, higher mortality in patients receiving an inappropriate shock has been reported in two randomized trials (SCD-HeFT and MADIT II) and one cohort of ICD patients undergoing remote monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Quality of life'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Lead failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Modern devices are noncommitted, meaning that they will reconfirm the rhythm prior to shock delivery; this feature reduces the likelihood of inappropriate shocks for nonsustained VT.",
"   </p>",
"   <p>",
"    Additional programming and dual chamber devices can reduce the frequency of inappropriate shocks. Dual chamber devices have an atrial lead for sensing and atrial antitachycardia pacing, can effectively detect specific atrial and ventricular arrhythmias, and can accurately discriminate between atrial",
"    <span class=\"nowrap\">",
"     tachycardia/atrial",
"    </span>",
"    flutter and atrial fibrillation. With appropriate programming, dual chamber ICDs have been shown to decrease inappropriate detection compared with single chamber devices [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/45\">",
"     45",
"    </a>",
"    ]. Other alternatives include antiarrhythmic drugs and catheter ablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H27332059#H27332059\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Supraventricular tachyarrhythmias (including sinus tachycardia and atrial fibrillation) discrimination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Appropriate shocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although potentially life-saving, appropriate shocks can also have an adverse effect on quality of life, including emotional problems and driving restriction. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Quality of life'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The frequency and time course of arrhythmic events were addressed in a report from the AVID trial of the 449 patients who were assigned to an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/40\">",
"     40",
"    </a>",
"    ]. The proportion of patients with an arrhythmic event (arrhythmic death, sustained ventricular arrhythmia, or a shock or antitachycardia pacing from the ICD) was 35 percent at three months, 53 percent at one year, and 68 percent at two years (",
"    <a class=\"graphic graphic_figure graphicRef69994 \" href=\"UTD.htm?36/35/37437\">",
"     figure 1",
"    </a>",
"    ). Approximately 46 percent had a first shock at one year; most of which (35 percent) were appropriate. First shocks or antitachycardia pacing after the second year were uncommon. Similar findings have been noted in other reports. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30024?source=see_link&amp;anchor=H4#H4\">",
"     \"Driving restrictions in patients with an implantable cardioverter-defibrillator\", section on 'Overall incidence of ventricular arrhythmias and ICD shocks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the systematic review cited above, the rate of appropriate shocks was two to three times higher than the rate of SCD in the control arms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/38\">",
"     38",
"    </a>",
"    ]. One explanation for this finding is that the ICDs treated some arrhythmias that would have terminated spontaneously. In order to minimize the number of appropriate shocks without compromising patient safety, several ICD programming strategies have been developed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing the duration of the arrhythmia necessary to trigger a therapy (eg, from 16 to 24 beats) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antitachycardia pacing (ATP), which should terminate at least 90 percent of episodes of persistent VT [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/39,48\">",
"       39,48",
"      </a>",
"      ]. Even rapid monomorphic VT is frequently terminated by ATP, and the risk of acceleration to VF requiring a shock is relatively low [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H16#H16\">",
"       \"General principles of the implantable cardioverter-defibrillator\", section on 'Antitachycardia pacing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other adjunctive therapies include antiarrhythmic drugs (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ), which were given for frequent shocks to 18 percent of patients with an ICD in the AVID trial, and catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested an increase in ventricular arrhythmias after the implantation of an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/38,50\">",
"     38,50",
"    </a>",
"    ]. There is no direct evidence demonstrating that ICDs are arrhythmogenic, and the possible mechanisms remain theoretical. However, the observation from clinical trials that appropriate ICD therapies occur at a greater frequency than SCD events in control groups suggests that potential proarrhythmic mechanisms should be investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanisms by which an ICD may promote ventricular arrhythmias include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The implanted lead may be arrhythmogenic. Early after implantation, the lead may trigger arrhythmias due to mechanical stimulation or irritation of the local myocardium. Later, fibrosis at the site of implantation may create arrhythmic substrate.",
"     </li>",
"     <li>",
"      Poor sensing by the ventricular lead, leading to inappropriate pacing during a vulnerable period of repolarization.",
"     </li>",
"     <li>",
"      Ventricular pacing may initiate reentry at the site of a prior infarction.",
"     </li>",
"     <li>",
"      Right ventricular pacing can cause dyssynchrony and exacerbate heart failure, resulting in a greater risk of ventricular arrhythmias.",
"     </li>",
"     <li>",
"      \"Normal\" bradycardia pacing operation may result in \"short-long-short\" pacing sequences, which may induce ventricular tachyarrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biventricular pacing, although it can reduce SCD risk overall, may increase the arrhythmic risk in some patients due to an abnormal sequence of depolarization and repolarization wavefronts, with resulting heterogeneity of repolarization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dispersion of refractoriness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over the longer term, supraventricular arrhythmias may also be induced by a shock. Atrial fibrillation, for example, commonly follows a shock which, in turn, may lead to spurious shocks if there is a rapid ventricular response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/52\">",
"     52",
"    </a>",
"    ]. The proposed mechanism for the induction of atrial fibrillation is shock intensity and energy delivery during the atrial vulnerable period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/53\">",
"     53",
"    </a>",
"    ]. The risk of induction of atrial fibrillation is increased in systems that include a lead in the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Electrical storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients receive multiple shocks within a short period of time. A common cause for multiple shocks is atrial fibrillation with rapid ventricular rates, which can be interpreted by the ICD as VT or VF, resulting in inappropriate shocks. Another cause is electrical storm. Electrical storm, also known as arrhythmic storm, refers to frequent recurrences of VT or VF (eg, three or more episodes during a 24 hour period). This is a relatively rare phenomenon and terminology and definitions vary. Among patients with an ICD, electrical storm may trigger repeated appropriate discharges (defibrillator storm).",
"   </p>",
"   <p>",
"    The incidence, triggers, clinical presentation, and treatment of electrical storm and incessant VT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=see_link\">",
"     \"Electrical storm and incessant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICDs may result in an increased incidence of heart failure (HF), particularly in patients with systolic dysfunction, by one of two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right ventricular pacing, producing ventricular dyssynchrony.",
"     </li>",
"     <li>",
"      Improved long-term survival in patients with advanced cardiac disease can result in patients living long enough for HF to develop or progress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of cardiac pacing in heart failure\", section on 'Implantable cardioverter-defibrillators'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Increased defibrillation threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defibrillation threshold (DFT, also called defibrillation energy requirement) is usually &le;15 joules and often &lt;10 joules with biphasic shocks and improved lead systems. When the DFT is high (over 20 joules), high energy devices, reversed energy polarity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional lead placements are used to achieve an adequate safety margin. Rarely, epicardial lead placement is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H19#H19\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Defibrillation threshold'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequent ICD discharges may produce a secondary increase in the DFT due to intense fibrosis and cumulative damage at the ICD electrode-myocardial interface [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, in the absence of any changes in the clinical status of the patient, DFTs with current transvenous lead systems are generally stable over time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more common problem is that patients with frequent appropriate shocks may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , which can increase the DFT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/58\">",
"     58",
"    </a>",
"    ]. The NASPE (now Heart Rhythm Society) guidelines for amiodarone therapy recommend that, whenever amiodarone is initiated in a patient with an ICD, a noninvasive ICD evaluation or an electrophysiology study should be performed to test for adverse drug-device interactions once loading is complete [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/59\">",
"     59",
"    </a>",
"    ]. In the OPTIC trial, however, the increase in DFT related to amiodarone was quite small, calling into question the necessity of verifying the defibrillation safety margin in many patients initiated on amiodarone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=see_link&amp;anchor=H5#H5\">",
"     \"Implantable cardioverter-defibrillators: Patient follow-up\", section on 'Defibrillation function testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There appears to be a circadian variation in the DFT, which has a morning peak that is 16 percent higher than that measured after noon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, the failed first shock rate is higher in the morning compared to other times during the day (25 versus 7 to 17 percent in one report). This variability may be most important in patients with high DFTs in whom a 10 joule safety margin becomes more difficult to attain.",
"   </p>",
"   <p>",
"    A rare cause of an increase in DFT and possible ICD failure is a pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Electromagnetic interference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since reliable function of the ICD depends upon proper sensing of the electrical activity of the heart, a potential concern is electromagnetic interference from external sources, including cellular telephones, welding equipment, motor-generator systems, and surveillance systems (",
"    <a class=\"graphic graphic_table graphicRef51277 \" href=\"UTD.htm?25/15/25852\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=see_link\">",
"     \"Cardiac device interactions with electromagnetic fields\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interference with ICD function can occur during noncardiac surgery as a result of electrical current generated by electrocautery, as well as during magnetic resonance imaging. Issues related to electrosurgery and MRI scanning and potential interactions with implanted cardiac devices are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link&amp;anchor=H18157871#H18157871\">",
"     \"Overview of electrosurgery\", section on 'Electrosurgery and implantable devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICD is often associated with deleterious psychosocial effects, with as many as 50 percent of recipients reporting elevated levels of anxiety and depression resulting from the fear of ICD discharge, device failure, decrease in physical activity, and negative life style changes (such as the inability to drive or to return to work) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/8,66-73\">",
"     8,66-73",
"    </a>",
"    ]. Some patients develop severe psychiatric problems after receiving appropriate shocks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency and severity of these psychosocial effects can be illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 119 patients, most described the shocks from the ICD as severe [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/66\">",
"       66",
"      </a>",
"      ]. Common descriptions were a blow to the body or a spasm causing the body to jump. Twenty-three percent dreaded the shocks and 5 percent said they would prefer to be without the ICD and take their chances. However, most patients tolerated the shocks because they are lifesaving.",
"     </li>",
"     <li>",
"      Another study of 70 patients noted an association between the number of shocks received and the likelihood of mood disturbances, ranging from 9 percent among those with less than four shocks to 55 percent in those with more than 10 shocks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of 800 patients from the AVID trial of secondary prevention, the ICD and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      were associated with similar alterations in quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/70\">",
"       70",
"      </a>",
"      ]. A reduction in physical functioning and mental well-being was largely related to the occurrence of any shocks from the ICD and to adverse side effects from the ICD or drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lower level of psychologic well being was noted after ICD implantation for the primary prevention of SCD in the CABG Patch trial, but overall health-related quality of life (HRQL) was not affected by ICD implantation in the DEFINITE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In both trials, receipt of one or more shocks adversely impacted some measures of quality of life.",
"   </p>",
"   <p>",
"    Efforts should be made to reduce the frequency of both appropriate and inappropriate shocks if they are common enough to interfere with the quality of life. The degree of anxiety and depression can also be reduced by the use of group and individual support and behavioral, cognitive, and relaxation therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/19/5434/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Appropriate shocks'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Inappropriate shocks'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The safety of driving in patients with an ICD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30024?source=see_link\">",
"     \"Driving restrictions in patients with an implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       \"Patient information: Sudden cardiac arrest (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5193057\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of implantable cardioverter-defibrillator (ICD) malfunction is difficult to determine due to inconsistent definitions of what constitutes a complication or malfunction and the lack of mandatory reporting of such data. Complications may be related to the implantation procedure, lead or pulse generator complications, arrhythmias, or other miscellaneous issues (eg, effect on quality of life):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Periprocedural complications of ICD placement include bleeding, infection, pneumothorax, cardiac perforation, lead dislodgement, and rarely death. The overall incidence of periprocedural complications increases with the age of the patient, but it has significantly decreased with the transition from abdominal implantations to pectoral implantations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Procedural complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lead-related problems include infection, as noted above, lead dislodgement, fracture, and insulation defects. The likelihood of lead-related complications appears to be significantly higher with subclavian compared to cephalic vein access and with an abdominal versus a pectoral generator site. Most lead dislodgements and infections occur in the first three months post-implantation, while lead fractures continue to occur during follow-up. On rare occasions, transvenous leads can disrupt normal functioning of the tricuspid valve, resulting in severe tricuspid regurgitation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lead complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications related to the pulse generator are uncommon, occurring in less than 2 percent of patients, and include migration of the device, skin erosion, and necrosis (due to the size and weight of the generator) as well as premature battery depletion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pulse generator complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inappropriate shocks occur in 20 to 25 percent of patients with an ICD, primarily due to supraventricular tachyarrhythmias, although electrical noise, inappropriate sensing, and ICD malfunction (eg, lead fracture) can also result in inappropriate shocks. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Inappropriate shocks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Having an ICD has been associated with deleterious psychosocial effects, including anxiety and depression resulting from the fear of ICD discharge, device failure, decrease in physical activity, and negative life style changes (such as the inability to drive or to return to work). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Quality of life'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/1\">",
"      Pfeiffer D, Jung W, Fehske W, et al. Complications of pacemaker-defibrillator devices: diagnosis and management. Am Heart J 1994; 127:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/2\">",
"      Kron J, Herre J, Renfroe EG, et al. Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 2001; 141:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/3\">",
"      DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med 2003; 349:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/4\">",
"      Rosenqvist M, Beyer T, Block M, et al. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Circulation 1998; 98:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/5\">",
"      Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006; 295:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/6\">",
"      Maisel WH. Pacemaker and ICD generator reliability: meta-analysis of device registries. JAMA 2006; 295:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/7\">",
"      Kuck KH, Cappato R, Siebels J, R&uuml;ppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/8\">",
"      Atwater BD, Daubert JP. Implantable cardioverter defibrillators: risks accompany the life-saving benefits. Heart 2012; 98:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/9\">",
"      Dewland TA, Pellegrini CN, Wang Y, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol 2011; 58:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/10\">",
"      van Rees JB, de Bie MK, Thijssen J, et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 2011; 58:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/11\">",
"      Freeman JV, Wang Y, Curtis JP, et al. Physician procedure volume and complications of cardioverter-defibrillator implantation. Circulation 2012; 125:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/12\">",
"      Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med 2010; 170:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/13\">",
"      Gold MR, Peters RW, Johnson JW, Shorofsky SR. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol 1996; 28:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/14\">",
"      Al-Khatib SM, Lucas FL, Jollis JG, et al. The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol 2005; 46:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/15\">",
"      Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA 2009; 301:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/16\">",
"      Gould PA, Krahn AD, Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006; 295:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/17\">",
"      Mehta D, Nayak HM, Singson M, et al. Late complications in patients with pectoral defibrillator implants with transvenous defibrillator lead systems: high incidence of insulation breakdown. Pacing Clin Electrophysiol 1998; 21:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/18\">",
"      Zuber M, Huber P, Fricker U, et al. Assessment of the subclavian vein in patients with transvenous pacemaker leads. Pacing Clin Electrophysiol 1998; 21:2621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/19\">",
"      Eckstein J, Koller MT, Zabel M, et al. Necessity for surgical revision of defibrillator leads implanted long-term: causes and management. Circulation 2008; 117:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/20\">",
"      Maisel WH, Kramer DB. Implantable cardioverter-defibrillator lead performance. Circulation 2008; 117:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/21\">",
"      Ellenbogen KA, Wood MA, Shepard RK, et al. Detection and management of an implantable cardioverter defibrillator lead failure: incidence and clinical implications. J Am Coll Cardiol 2003; 41:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/22\">",
"      Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of &gt;10 years. Circulation 2007; 115:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/23\">",
"      Hauser RG, Kallinen LM, Almquist AK, et al. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 2007; 4:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/24\">",
"      Kallinen LM, Hauser RG, Lee KW, et al. Failure of impedance monitoring to prevent adverse clinical events caused by fracture of a recalled high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 2008; 5:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/25\">",
"      van Rees JB, van Welsenes GH, Borleffs CJ, et al. Update on small-diameter implantable cardioverter-defibrillator leads performance. Pacing Clin Electrophysiol 2012; 35:652.",
"     </a>",
"    </li>",
"    <li>",
"     Groves R. Urgent medical device information. Medtronic, Inc. October 15, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/27\">",
"      Hauser RG, Abdelhadi R, McGriff D, Retel LK. Deaths caused by the failure of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm 2012; 9:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/28\">",
"      Gunderson BD, Patel AS, Bounds CA, et al. An algorithm to predict implantable cardioverter-defibrillator lead failure. J Am Coll Cardiol 2004; 44:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/29\">",
"      Swerdlow CD, Gunderson BD, Ousdigian KT, et al. Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrillator leads. Circulation 2008; 118:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/30\">",
"      Lin G, Nishimura RA, Connolly HM, et al. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. J Am Coll Cardiol 2005; 45:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/31\">",
"      Eleid MF, Blauwet LA, Cha YM, et al. Bioprosthetic tricuspid valve regurgitation associated with pacemaker or defibrillator lead implantation. J Am Coll Cardiol 2012; 59:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/32\">",
"      Maisel WH, Sweeney MO, Stevenson WG, et al. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. JAMA 2001; 286:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/33\">",
"      Korte T, Jung W, Schlippert U, et al. Prospective evaluation of shoulder-related problems in patients with pectoral cardioverter-defibrillator implantation. Am Heart J 1998; 135:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/34\">",
"      Boyle NG, Anselme F, Monahan KM, et al. Twiddler's syndrome variants in ICD patients. Pacing Clin Electrophysiol 1998; 21:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/35\">",
"      Carnero-Varo A, P&eacute;rez-Paredes M, Ruiz-Ros JA, et al. \"Reel Syndrome\": a new form of Twiddler's syndrome? Circulation 1999; 100:e45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/36\">",
"      Gould PA, Gula LJ, Champagne J, et al. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm 2008; 5:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/37\">",
"      Hauser RG, Hayes DL, Almquist AK, et al. Unexpected ICD pulse generator failure due to electronic circuit damage caused by electrical overstress. Pacing Clin Electrophysiol 2001; 24:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/38\">",
"      Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol 2006; 97:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/39\">",
"      Wood MA, Stambler BS, Damiano RJ, et al. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group. J Am Coll Cardiol 1994; 24:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/40\">",
"      Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 2003; 14:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/41\">",
"      Dichtl W, Wolber T, Paoli U, et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clin Cardiol 2011; 34:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/42\">",
"      Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/43\">",
"      van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011; 57:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/44\">",
"      Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation 2010; 122:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/45\">",
"      Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation 2006; 113:2871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/46\">",
"      Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/47\">",
"      Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/48\">",
"      Schaumann A, von zur M&uuml;hlen F, Herse B, et al. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 1998; 97:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/49\">",
"      Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001; 142:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/50\">",
"      B&ouml;cker D, Block M, Isbruch F, et al. Comparison of frequency of aggravation of ventricular tachyarrhythmias after implantation of automatic defibrillators using epicardial versus nonthoracotomy lead systems. Am J Cardiol 1993; 71:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/51\">",
"      Sweeney MO, Ruetz LL, Belk P, et al. Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia? J Am Coll Cardiol 2007; 50:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/52\">",
"      Florin TJ, Weiss DN, Peters RW, et al. Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators. Am J Cardiol 1997; 80:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/53\">",
"      Katz A, Sweeney RJ, Gill RM, et al. Relation of atrial refractoriness to upper and lower limits of vulnerability for atrial fibrillation/flutter following implantable ventricular defibrillator shocks. Circulation 1999; 100:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/54\">",
"      Epstein AE, Kay GN, Plumb VJ, et al. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation 1998; 98:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/55\">",
"      Martin DT, John R, Venditti FJ Jr. Increase in defibrillation threshold in non-thoracotomy implantable defibrillators using a biphasic waveform. Am J Cardiol 1995; 76:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/56\">",
"      Newman D, Barr A, Greene M, et al. A population-based method for the estimation of defibrillation energy requirements in humans. Assessment of time-dependent effects with a transvenous defibrillation system. Circulation 1997; 96:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/57\">",
"      Rashba EJ, Olsovsky MR, Shorofsky SR, et al. Temporal decline in defibrillation thresholds with an active pectoral lead system. J Am Coll Cardiol 2001; 38:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/58\">",
"      Zhou L, Chen BP, Kluger J, et al. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/59\">",
"      Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/60\">",
"      Hohnloser SH, Dorian P, Roberts R, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006; 114:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/61\">",
"      Venditti FJ Jr, John RM, Hull M, et al. Circadian variation in defibrillation energy requirements. Circulation 1996; 94:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/62\">",
"      Luria D, Stanton MS, Eldar M, Glikson M. Pneumothorax: an unusual cause of ICD defibrillation failure. Pacing Clin Electrophysiol 1998; 21:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/63\">",
"      Cohen TJ, Lowenkron DD. The effects of pneumothorax on defibrillation thresholds during pectoral implantation of an active can implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1998; 21:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/64\">",
"      Pinski SL, Trohman RG. Interference in implanted cardiac devices, Part I. Pacing Clin Electrophysiol 2002; 25:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/65\">",
"      Pinski SL, Trohman RG. Interference in implanted cardiac devices, part II. Pacing Clin Electrophysiol 2002; 25:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/66\">",
"      Ahmad M, Bloomstein L, Roelke M, et al. Patients' attitudes toward implanted defibrillator shocks. Pacing Clin Electrophysiol 2000; 23:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/67\">",
"      Herrmann C, von zur M&uuml;hen F, Schaumann A, et al. Standardized assessment of psychological well-being and quality-of-life in patients with implanted defibrillators. Pacing Clin Electrophysiol 1997; 20:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/68\">",
"      Sears SF, Todaro JF, Urizar G, et al. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol 2000; 23:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/69\">",
"      Burgess ES, Quigley JF, Moran G, et al. Predictors of psychosocial adjustment in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1997; 20:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/70\">",
"      Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002; 105:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/71\">",
"      Namerow PB, Firth BR, Heywood GM, et al. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. Pacing Clin Electrophysiol 1999; 22:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/72\">",
"      Passman R, Subacius H, Ruo B, et al. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med 2007; 167:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/73\">",
"      Kamphuis HC, de Leeuw JR, Derksen R, et al. Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. Europace 2003; 5:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/74\">",
"      Bourke JP, Turkington D, Thomas G, et al. Florid psychopathology in patients receiving shocks from implanted cardioverter-defibrillators. Heart 1997; 78:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/75\">",
"      Kohn CS, Petrucci RJ, Baessler C, et al. The effect of psychological intervention on patients' long-term adjustment to the ICD: a prospective study. Pacing Clin Electrophysiol 2000; 23:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/19/5434/abstract/76\">",
"      Tchou PJ, Piasecki E, Gutmann M, et al. Psychological support and psychiatric management of patients with automatic implantable cardioverter defibrillators. Int J Psychiatry Med 1989; 19:393.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 989 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5434=[""].join("\n");
var outline_f5_19_5434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5193057\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Explantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCEDURAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Operator characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Explantation and generator change",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LEAD COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lead failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lead removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PULSE GENERATOR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Shoulder-related problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Twiddler's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Electronic circuit damage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Inappropriate shocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Appropriate shocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Electrical storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MISCELLANEOUS ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Increased defibrillation threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Electromagnetic interference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5193057\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/989|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/35/37437\" title=\"figure 1\">",
"      Frequency of arrhythmia and ICD events in AVID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/15/25852\" title=\"table 1\">",
"      EMI with cardiac devices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=related_link\">",
"      Cardiac device interactions with electromagnetic fields",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30921?source=related_link\">",
"      Cardiac implantable electronic device lead removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30024?source=related_link\">",
"      Driving restrictions in patients with an implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=related_link\">",
"      Electrical storm and incessant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=related_link\">",
"      Implantable cardioverter-defibrillators: Patient follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_19_5435="Causes of elevated BSAP";
var content_f5_19_5435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F87761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F87761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of elevated bone-specific alkaline phosphatase",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Severe hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Paget's disease of bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Metastatic carcinoma to bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Osteomalacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Severe 25-hydroxyvitamin D deficiency (&lt;10 ng/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Recent large bone fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Immobilization/space travel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Treatment with teriparatide or 1-84 parathyroid hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. High bone turnover osteoporosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Miller PD. Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 2012; 41:613.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5435=[""].join("\n");
var outline_f5_19_5435=null;
var title_f5_19_5436="Early-onset GBS infection rx";
var content_f5_19_5436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous treatment of early-onset group B streptococcal infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site(s) of infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Empirical therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definitive therapy*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Bacteremia/sepsis/pneumonia",
"       </td>",
"       <td>",
"        Ampicillin 150 mg/kg every 12 hours",
"       </td>",
"       <td rowspan=\"3\">",
"        Penicillin G: 150,000 to 200,000 units/kg per day divided every 6 to 8 hours",
"       </td>",
"       <td rowspan=\"3\">",
"        10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin 4 mg/kg every 24 hours for infants born at &ge;35 weeks gestation; 3 mg/kg every 24 hours for infants born at &lt;35 weeks gestation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Meningitis",
"       </td>",
"       <td>",
"        Ampicillin 100 to 150 mg/kg every&nbsp;8 hours",
"       </td>",
"       <td rowspan=\"3\">",
"        Penicillin G: 250,000 to 450,000 units/kg per day divided every 8 hours",
"       </td>",
"       <td rowspan=\"3\">",
"        14 to 21 days",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin 4 mg/kg every 24 hours for infants born at &ge;35 weeks gestation; 3 mg/kg every 24 hours for infants born at &lt;35 weeks gestation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GBS: Group B streptococcus; CSF: cerebrospinal fluid.",
"     <br>",
"      * Definitive therapy should not be started until GBS is identified by culture; clinical improvement is evident; and for meningitis, CSF is sterile at 24 to 48 hours of therapy.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       14 days is sufficient for uncomplicated cases of GBS meningitis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.680.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5436=[""].join("\n");
var outline_f5_19_5436=null;
var title_f5_19_5437="Classification of neutropenias";
var content_f5_19_5437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of neutropenias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rickettsial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral - eg, hepatitis B, Epstein-Barr virus, HIV, HCV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Collagen vascular diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Felty's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Complement activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Filtration leukapheresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drug-induced neutropenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clozapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thionamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Autoimmune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign of childhood and adult chronic form",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Large granular lymphocyte syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoimmune neutropenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transfusion reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic idiopathic neutropenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pure white cell aplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersplenism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nutritional deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcoholism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin B12 or folate deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Copper deficiency with low ceruloplasmin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diseases affecting the bone marrow*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postchemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoplasia (aplastic anemia, Fanconi anemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute and chronic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe congenital neutropenia (Kostmann's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shwachman-Diamond-Oski syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelokathexis/neutropenia with tetraploid leukocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclic neutropenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chediak-Higashi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reticular dysgenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyskeratosis congenita",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Neutropenia usually does not occur as an isolated defect in these disorders.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Partial list only. See Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer 2007; 49:609 for a more complete classification.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5437=[""].join("\n");
var outline_f5_19_5437=null;
var title_f5_19_5438="Meibomian gland dysfunction 2";
var content_f5_19_5438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Expression of a cloudy meibomian gland secretion, which obscures the underlying meibomian orifices. A droplet overlies the inflamed marginal conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5438=[""].join("\n");
var outline_f5_19_5438=null;
var title_f5_19_5439="Tularemia adenitis";
var content_f5_19_5439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tularemia adenitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulceroglandular tularemia involving the submental node characterized by a papular lesion in the drainage field of the inflamed lymph node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_19_5439=[""].join("\n");
var outline_f5_19_5439=null;
